TITLE: Longitudinal glioma monitoring via cerebrospinal fluid cell-free DNA: one patient
 at a time.

AUTHORS: Cecile Riviere-Cazaux BS¹, Xiaoxi Dong PhD², Wei Mo MD PhD², Chao 3 Dai PhD², Lucas P. Carlstrom MD PhD^{1,3}, Amanda Munoz-Casabella MD¹, Rahul 4 Kumar MD PhD¹, Keyvan Ghadimi MD^{1,4}, Cody L. Nesvick MD¹, Katherine M. Andersen 5 PA-C¹, Matthew D. Hoplin MS¹, Nicholas Canaday¹, Ignacio Jusue-Torres MD¹, Noor 6 Malik MBBS¹, Jian L. Campian MD PhD⁵, Michael W. Ruff MD⁶, Joon H. Uhm MD⁶, 7 Jeanette E. Eckel Passow PhD⁷, Timothy J. Kaufmann MD MS⁸, David M. Routman 8 MD⁹, Sani H. Kizilbash MD MPH⁵, Arthur E. Warrington PhD^{1,6}, Robert B. Jenkins MD 9 PhD¹⁰, Pan Du PhD², Shidong Jia MD PhD², Terry C, Burns MD PhD¹ 10 11 **AFFILIATIONS:** Departments of ¹Neurological Surgery, ⁵Medical Oncology, ⁶Neurology, ⁷Quantitative 12 Health Sciences, ⁸Radiology, ⁹Radiation Oncology, and ¹⁰Laboratory Medicine and 13 Pathology, Mayo Clinic, Rochester, MN, USA 14 ²Predicine, Inc., Hayward, CA, USA 15 ³Department of Neurological Surgery, The Ohio State University, Columbus, OH, USA 16 ⁴Leo M. Davidoff Department of Neurological Surgery, Albert Einstein College of 17 18 Medicine, Bronx, NY, USA **RUNNING TITLE:** Longitudinal glioma CSF cell-free DNA 19 20 **CORRESPONDENCE:** Terry C. Burns, MD, PhD Department of Neurosurgery – Mayo Clinic 21 200 First St. SW 22

23 Mayo Clinic

- 1 Rochester, MN, 55905
- 2 burns.terry@mayo.edu
- 3 Fax: 507-284-5206
- 4 Phone: 507-284-4871
- 5 **KEYWORDS:** glioma; biomarker; cerebrospinal fluid; monitoring; cell-free DNA
- 6 **WORD COUNT:** 2,998
- 7 **# FIGURES:** 5
- 8 **# TABLES:** 0
- 9

1 **QUESTION:** What is the feasibility of obtaining longitudinal intracranial cerebrospinal 2 fluid cell-free DNA from patients with high-grade gliomas to evaluate changes during 3 treatment? 4 FINDING: In this case series, we find that CSF cfDNA can feasibly be obtained 5 throughout treatment via CSF access devices. We find that changes in tumor fraction or 6 tumor-associated variant allele frequencies (VAFs) may correlate with disease 7 trajectory, with VAFs positively correlating to other tumor-associated candidate 8 biomarkers.

9 MEANING: Longitudinal cerebrospinal cell-free DNA may inform the impact of treatment
 10 throughout a specific patient's disease course, from the time of resection through
 11 radiographic progression.

1 **ABSTRACT:**

- 2 **IMPORTANCE:** Current methods for glioma treatment response assessment are
- 3 limited. Intracranial cerebrospinal fluid (CSF) may provide a previously untapped source
- 4 of longitudinal biomarkers, such as cell-free DNA (cfDNA), for disease monitoring.
- 5 **OBJECTIVE:** To assess the feasibility of obtaining longitudinal intracranial CSF cfDNA
- 6 from patients with gliomas during their disease course.
- 7 **DESIGN:** This case series was initiated in 2021, with patients followed until last clinical
- 8 follow-up (death or present time).
- 9 **SETTING:** This single-center study was conducted at a large academic medical center.
- 10 **PARTICIPANTS:** Adults with gliomas were recruited for longitudinal intracranial CSF

11 collection using 1) Ommaya reservoirs, from which CSF would be sampled on at least

- 12 two separate occasions, or 2) CSF collection from other clinically indicated CSF access
- 13 devices, such as ventriculoperitoneal (VP) shunts.
- 14 **INTERVENTIONS:** CSF was collected from Ommaya reservoirs in four patients and
- 15 from an existing VP shunt in one patient.
- 16 MAIN OUTCOMES AND MEASURES: The study aimed to collect CSF for biobanking

17 and biomarker discovery, with the hypothesis that CSF could serve as a source of

- 18 longitudinally acquirable biomarkers.
- 19 **RESULTS:** Five patients (2 females, 3 males; median: 40 years, range 32-64 years)
- 20 underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n=4/5
- 21 patients) or VP shunt (n=1/5). Three patients had glioblastoma and two had
- 22 astrocytoma, IDH-mutant, grade 4. In total, thirty-five CSF samples were obtained
- 23 (median: 3.80 mL; 0.5-5 mL), with 30 (85.7%) yielding sufficient cfDNA for Next-
- 24 Generation Sequencing (n=28) or Low-Pass Whole Genome sequencing (all samples).
- 25 Tumor fraction was found to increase with radiographic progression. Changes in variant
- 26 allelic frequencies (VAFs) may be seen within individual patients after resection and
- 27 chemoradiation. In two patients, changes in tumor-specific IDH1 VAF correlated with
- 28 CSF D-2-hydroxyglutarate levels, the oncometabolite of IDH mutant tumors. Copy
- 29 number burden (CNB) decreased below the limit of quantification during treatment.
- 30 **CONCLUSIONS AND RELEVANCE:** Longitudinal CSF cfDNA can feasibly be obtained
- 31 via CSF access devices in patients with gliomas during their disease course. Ongoing

- 1 studies will evaluate hypotheses generated in this case series regarding how
- 2 longitudinal CSF cfDNA could be utilized to sensitively detect changes in disease
- 3 burden.
- 4 Trial Registration: NCT04692324 <u>https://clinicaltrials.gov/study/NCT04692324;</u>
- 5 NCT04692337 https://clinicaltrials.gov/study/NCT04692337

1 INTRODUCTION

2	Few tools exist to monitor glioma burden and biological response to standard-of-
3	care chemoradiation or experimental therapies. The availability of serial biopsy samples
4	has enabled rapid progress in monitoring for some cancers, including breast cancer,
5	melanoma, and blood-based cancers ¹⁻⁵ . However, the requirement for brain biopsy to
6	obtain glioma tissue during treatment has hindered monitoring ^{6, 7} . MRI is standard-of-
7	care for treatment response assessment, but its sensitivity and specificity remain a
8	limitation ^{8, 9} . Based on well-established cancer genomic markers, cell-free DNA (cfDNA)
9	in liquid biopsies has become of growing interest for cancer detection and monitoring,
10	particularly in plasma ¹⁰⁻¹³ . Numerous trials are now leveraging cfDNA to guide
11	therapeutic decision making ¹⁴⁻¹⁹ . However, the blood-brain barrier has hampered
12	detection of tumor-associated cfDNA in plasma, also known as cell-tumor DNA (ctDNA),
13	with studies reporting a low detection rate, often between 10-50% ²⁰⁻²² .
14	Studies in other cancers, such as prostate cancer ^{23, 24} , demonstrate that proximal
15	fluids improve detection of tumor-derived biomarkers ²⁵ . Similarly, as the liquid source
16	closest to the tumor, cfDNA detection rates in cerebrospinal fluid (CSF) from patients
17	with brain tumors, including gliomas and brain metastases, increase to an average of
18	approximately 85% in more recent studies ²⁶⁻³⁰ . CSF cfDNA studies in glioma have
19	repeatedly demonstrated the superiority of CSF to plasma for cfDNA detection ^{27, 29} , as
20	well as the fidelity of cfDNA for reporting mutations detected in tissue ³¹ . Instead of
21	targeted sequencing for mutations, recent studies have increasingly utilized Next-
22	Generation Sequencing (NGS) or low-pass whole genome sequencing (LP-WGS) to

characterize the global genomic landscape of glioma CSF cfDNA for tumor diagnosis
 and identification of treatment-resistant mutations^{32, 33}.

3 Longitudinal CSF cfDNA may be useful for disease monitoring. A previous study 4 reported on changes in tumor-associated mean allele frequencies between two CSF 5 timepoints²⁷. However, to our knowledge, no study has obtained longitudinal intracranial 6 CSF samples for cfDNA analysis during a patient's disease course. We hypothesized 7 that intracranial CSF could be an abundant source of longitudinally acquirable cfDNA. 8 Herein, we report our initial experience utilizing CSF access devices to determine how 9 CSF cfDNA changes during treatment in patients with glioblastoma (GBM) or 10 astrocytoma, IDH mutant (CNS WHO grade 4). Moreover, we identify remaining 11 questions to guide ongoing and future studies aiming to utilize CSF cfDNA for disease 12 burden monitoring during standard-of-care or clinical trials for patients with gliomas.

13 MATERIALS AND METHODS

14 Patient cohort

15 Informed consent was provided by each patient for collection of CSF in the 16 operating room or clinic under biobanking, CSF biomarkers (NCT04692324, to obtain 17 CSF from clinically indicated CSF devices), or Ommaya reservoir (NCT04692337, for 18 research) protocols, each of which were approved via the Mayo Clinic Institutional 19 Review Board. For all studies, inclusion criteria included adult patients with known or 20 suspected brain neoplasms. For NCT04692337, inclusion criteria also included planned 21 resection of the neoplasm and willingness to have the Ommaya sampled on 2 future 22 occasions. Exclusion criteria for NCT04692324 included a clinical contraindication to the

intended route of CSF access, and for NCT04692337, any prior wound infection or
 contraindication to the Ommaya.

3 CSF collection

4 Patients had CSF access devices for longitudinal CSF access (4 research 5 Ommaya reservoirs, 1 clinical ventriculoperitoneal shunt). The ventricular catheters 6 were placed into the resection cavity, which contacted the ventricular system in each 7 patient. CSF was sampled intra-operatively from the surgical field. In follow-up cases, 8 20 mL of CSF was slowly withdrawn from the Ommaya reservoir or shunt. CSF was 9 maintained on ice or at 4°C (typically <1 hour), then centrifuged at 400G for 10 minutes 10 at 4°C. De-identified aliquots were stored at -80°C in cryovials. Samples were annotated 11 to include the known pathology, date of collection, and ongoing treatment, as well as 12 technical variables including sample color, collection, and processing times.

13 Cell-free DNA extraction and sequencing

14 Thirty-five CSF samples were analyzed across the 5 patients (median number of 15 samples per patient: 7 (range: 3-12); median volume per sample: 3.80 mL (range: 0.5-5 16 mL)), of which 30 (85.7%) yielded sufficient cfDNA for testing. Patient samples were 17 analyzed using two comprehensive NGS platforms, PredicineCARE and 18 PredicineSCORE (Predicine, Inc.), to generate genomic aberration profiles and derive 19 genome-wide copy number burden (CNB) score. Briefly, cell-free DNA (cfDNA) were 20 subjected to library construction. PredicineCARE targeted hybridization enrichment 21 assay was used to generate the landscape of genomic alterations including single-22 nucleotide variants (SNV), insertions and deletions (indels), CNVs, and gene fusions³⁴⁻ 23 ³⁷. PredicineSCORE low pass whole genome sequencing assay was used to generate

copy number profiles and genome-wide copy number burden (CNB) score, which
 represents a comprehensive genome-wide measure of copy number status, including
 amplifications and deletions if any, across the entire chromosome arms. See
 Supplemental methods for further details.

5 **RESULTS**

6 Patient 24 – Recurrent glioblastoma

The first patient to enroll on our Ommaya reservoir trial (Patient 24 in our CSF 7 8 biobank) was a female in her late 50s with suspected recurrence of her GBM after 9 standard chemoradiation (Fig. 1A). At her first post-operative CSF sample on post-10 operative day (POD) 26 after re-resection, a new region of substantial periventricular 11 progression was observed on MRI, prompting initiation of lomustine (CCNU). At her 12 next sample on POD75, further progression was noted, prompting transition to bevacizumab. The final CSF sample was obtained on POD118, at which time MRI 13 14 showed ongoing progression on bevacizumab. She transitioned to hospice and passed 15 away on POD152.

16 Ventricular CSF was sent from the surgical field and was found to contain

17 insufficient cfDNA (0.00 ng/mL) for baseline testing (Fig. 1Bi). By contrast, the POD26

sample contained 9.95 ng/mL that decreased to 1.77 ng/mL after lomustine (POD75),

19 despite radiographic disease progression after lomustine. This sample was insufficient

20 for NGS, hampering evaluation of tumor fraction that otherwise increased 6.28x

between POD26 and POD118 (**Fig. 1Bii**). LP-WGS was also performed and revealed

that copy number burden (CNB) increased above the limit of quantification by POD118

23 (Fig. 1Biii). Trisomy 7, loss of 9p (including CDKN2A/B), and gains on chromosomes

19 and 20 were detectable on the copy number plot by POD118 (Fig. 1Ci).

1 Consistent with the patient's known EGFR-amplified tumor, the variant allele 2 frequency (VAF) for mutant EGFR increased from 3.21% to 44.84% between her pre-3 lomustine and post-bevacizumab samples (Fig. 1cii). The patient's glioma harbored a 4 TERT C228T mutation that was detectable at a VAF of 10.66% by the post-5 bevacizumab sample (POD118). 6 Initial observations generated by patient 24 (Fig. 1D) included that tumor fraction 7 and VAFs may increase with progression (Fig. 1Bii, 1Cii). CNB may also increase 8 above the estimated limit of quantification (CNB>7.5) (Fig. 1Biii). However, despite 9 radiographic progression at POD75, few data points were available due to limited 10 cfDNA abundance after lomustine. This raised the question of whether alkylating 11 therapy may decrease CSF cfDNA, even if ineffective. With these initial observations, 12 we sought to evaluate patients during therapy from the time of original diagnosis. 13 Patient 78 – Glioblastoma 14 Patient 78 (male in early 60s) underwent Ommaya placement during resection 15 of a cystic lesion that proved to be GBM (Fig. 2A). The patient enrolled in a trial of 16 pembrolizumab with standard chemoradiation. Imaging raised concern for progression around POD270, prompting initiation of regorafenib, a tyrosine kinase inhibitor. Further 17 18 radiographic progression prompted transition to bevacizumab, with radiographic 19 response. The patient transitioned to hospice and passed away on POD729. 20 CSF from a cortical sulcus and cyst fluid were both obtained during surgery, the 21 latter of which yielded 104.2x more cfDNA (Fig. 2Bi). Total cfDNA abundance, tumor 22 fraction, and CNB increased in post-resection CSF relative to the sulcal CSF sample

23 (Fig. 2Bi-iii), likely reflecting the combined effect of recent tissue disruption and

1 increased tumor contact with post-operatively sampled ventricular CSF. These 2 measures then decreased with chemoradiation and pembrolizumab (POD202 versus 3 21; Fig. 2Bi-iii). No CSF cfDNA was extractable at POD107 immediately after 4 chemoradiation. Despite suspected radiographic progression around POD270 which 5 prompted initiation of regorafenib, no cfDNA could be extracted from CSF obtained at POD245. CSF obtained during regorafenib treatment demonstrated increased total 6 7 cfDNA abundance, with CNB decreasing below the limit of quantification (POD 296; Fig. 8 **2Bi**; ii). cfDNA abundance declined with initiation of bevacizumab prior to increasing 9 again by POD471, suggesting relative variability in cfDNA abundance despite minimal 10 radiographic changes (Fig 2Bii). In contrast, CNB remained below the limit of 11 quantification (Fig. 2Biii). +7, -10, +19 and +20 and other alterations were observed on 12 the copy number plots on POD0 and could not be detected after chemoradiation and 13 pembrolizumab (Fig. 2Ci-ii). TP53 and TERT VAFs initially increased after 14 bevacizumab prior to decreasing by POD471 (Fig. 2Ciii; Supplemental Fig. 1A). In 15 sum, initial observations for patient 78 (Fig. 2D) included that resection may not 16 decrease CSF cfDNA even by POD21 (Fig. 2Bi). CNB and tumor-associated VAFs may 17 decrease during chemoradiation (Fig. 2Biii; Ciii). Increased radiographic enhancement, 18 but decreased CNB and VAFs, at POD296 prompted the question of whether 19 pseudoprogression could increase total CSF cfDNA. 20 Patient 79 – Glioblastoma 21 Patient 79 is a female in her early 30s who underwent resection for a GBM (Fig.

3A). Given an expected subtotal resection and the highly vascular nature of her tumor,

23 an EVD was also placed at the time of surgery in addition to her Ommaya reservoir.

MSH2 and MSH6 staining revealed loss of expression, diagnostic of defective DNA mismatch repair. Next Generation Sequencing revealed over 200 mutations supportive of a hypermutant phenotype. Considering literature support for immunotherapy in hypermutation phenotypes³⁸, she was treated with pembrolizumab, which began prior to chemoradiation. Radiographic progression near POD300 resulted in discontinuation of pembrolizumab and initiation of bevacizumab to which there was radiographic response.

8 Intra-operatively obtained CSF yielded 15.60 ng/mL of cfDNA that transiently 9 increased to 82.00 ng/mL when CSF was obtained from the EVD on POD2 (Fig. 3Bi). 10 In contrast, tumor fraction decreased from 0.597 to 0.368 (Fig. 3Bii), potentially 11 suggesting that much of the cfDNA on POD2 was from post-operative tissue disruption. 12 Interestingly, despite the hypermutated phenotype, this tumor lacked evidence of 13 chromosomal complexity, with a stably low CNB below the limit of quantification and no 14 obvious chromosomal alterations on the whole genome plots (Fig. 3Biii; 4Ci-iii), unlike 15 most GBMs that harbor +7/-10q alterations. In stark contrast, the longitudinal variant 16 allele frequency plot demonstrated marked evolution of mutations over time (Fig. 3Civ). 17 POD2 revealed variants not seen on POD0, likely reflecting incomplete sampling of a 18 heterogeneous lesion in the initial CSF. New variants seen on POD36 likely represent 19 ongoing disease evolution prior to chemotherapy.

In summary (**Fig. 3D**), samples from patient 79 suggested that early postoperative samples may have transiently increased cfDNA (**Fig. 3Bi**). Resection may expose more variants in a heterogeneous tumor, that may then evolve further prior to treatment (**Fig. 3Civ**). Given these findings, this patient's data raised the question of

1 whether a post-operative CSF sample may better sample or capture tumor

2 heterogeneity (**Fig. 3D**).

3 Patient 98 – Astrocytoma, IDH mutant (CNS WHO grade 4)

Patient 98 is a male in his early 40s who underwent resection of an astrocytoma,
IDH mutant (CNS WHO grade 4) and Ommaya placement (**Fig. 4A**). In addition to
standard-of-care chemoradiation, he participated in an immunotherapy trial wherein he
was randomized to either NT-I7 or placebo at an outside facility. No post-operative CSF
samples were obtained until POD146 after chemoradiation when MRI raised concern for
progression versus pseudoprogression.

10 Despite variable changes in cfDNA abundance and increasing radiographic 11 contrast enhancement, tumor fraction decreased and CNB fell below the limit of 12 guantification during treatment and observation (Fig. 4Bi-iii). Indeed, while contrast-13 enhancing volume increased, decreasing IDH1 VAF also correlated with decreasing 14 CSF D-2-hydroxyglutarate (D-2-HG) levels, an oncometabolite of IDH mutant tumors (Fig. 4Biv)³⁹. Gain of 2p, gain of 7q, loss of 9p (without CDKN2A/B homozygous 15 16 deletion), and loss of 10q, all common alterations in astrocytoma, IDH-mutant, were 17 detected in the POD0 sample, but these were no longer detectable by POD305 (Fig. 18 4Ci-ii). In addition to IDH1 (Fig. 4Biv), VAFs for most detected mutations decreased 19 with treatment, with only one of the originally detected variants present by POD361 20 when the patient was on observation (Fig. 4Ciii; Supplemental Fig. 1B).

In summary (Fig. 4D), observations from patient 98 suggested that CNB may
decrease below the limit of quantification with treatment (Fig. 4Biii), as seen with
patient 78 (Fig. 2Biii). Moreover, IDH1 VAF may correlate with changes in CSF D-2-HG

1 (Fig 4Biv). As with patient 78, we again guestioned whether pseudoprogression could 2 increase CSF cfDNA yield. Agreement between tumor fraction, IDH1 VAF, 2-HG, and 3 CNB despite increasing enhancing volume prompted the hypothesis that CSF cfDNA 4 may be superior to MRI for treatment response monitoring. 5 Patient 138 – Astrocytoma, IDH mutant (CNS WHO grade 4) 6 Patient 138 is a male in his early 30s who underwent pre-operative EVD 7 placement due to clinical decline with ventriculomegaly. His EVD was maintained after 8 tumor resection, which revealed an astrocytoma, IDH mutant (CNS WHO grade 4). Due 9 to difficulty weaning the EVD, a ventriculoperitoneal shunt was placed (Fig. 5A). By 10 POD214, radiographic disease progression was suspected, and the patient was initiated 11 on lomustine. 12 CSF was obtained from the patient's EVD prior to and after resection. cfDNA 13 abundance increased from 31.81 ng/mL to 50.22 ng/mL, while tumor fraction decreased 14 0.198 to 0.042 (Fig. 5Bi-ii). Tumor fraction then increased by 2.87x to 0.121 by 15 suspected progression on POD214 (Fig. 5Bii). CNB decreased and remained below the 16 limit of quantification after resection through POD214 (Fig. 5Biii). IDH1 VAF decreased 17 with resection prior to increasing at the time of suspected radiographic progression 18 (POD214), consistent with D-2-HG increasing from 0.4 to 1.02 μ M (Fig. 5Biv). 19 Chromosome 6p gain and 6q loss, 11q gain, and 13q loss, all common in astrocytoma, 20 IDH-mutant, were identified at POD0, although almost no copy number alterations could 21 be detected by POD214 (Fig. 5Ci-ii). TP53 VAF decreased with resection and 22 increased by POD214, along with the emergence of a GNAS mutation (Fig. 5Ciii).

Patient 138 yielded findings reminiscent of those seen in prior patients: 1) as with
patient 24, tumor fraction may increase with suspected disease progression (Fig. 5Bii);
2) as with patient 98 (Fig. 4Biv), IDH VAF may correlate with changes in D-2-HG (Fig.
5Biv), and 3) as with patient 79 (Fig. 3Bi), resection may transiently increase cfDNA
abundance in early post-operative samples (Fig. 5Bi). A remaining question was the
threshold at which to call disease progression based on cfDNA.

7 DISCUSSION

8 In this five-patient case series, we report our initial experience with longitudinal 9 intracranial CSF for cfDNA analysis in patients undergoing treatment for glioblastoma or 10 astrocytoma, IDH mutant, grade 4. Although preliminary, our findings provoke the 11 following hypotheses to be further tested: (1) Tumor fraction may increase with 12 suspected disease progression, (2) cfDNA abundance is variable across samples, but 13 may transiently increase post-operatively and with pseudoprogression, (3) changes in 14 mutational variants and their allelic frequencies may be seen within individual patients 15 via longitudinal CSF sampling, (4) CSF D-2-HG levels may correlate with changes in 16 IDH1 cfDNA, despite incongruent radiographic findings, and (5) CNB decreases below 17 the limit of quantification during treatment with current techniques. Key questions 18 included whether pseudoprogression could increase cfDNA abundance and importantly, 19 what is the required threshold of change in each cfDNA measure to call disease 20 progression.

CfDNA burden in other cancer types has been shown to increase with recent
 resection or treatment, likely due to disruption of the tissue resulting in release of
 cfDNA⁴⁰⁻⁴². Indeed, after resection, CSF cfDNA burden transiently increased for each

1	patient where CSF was obtained prior to and after resection, and remained elevated
2	even by POD21 in patient 78. As resection increases surgical debris that also has its
3	own cell-free DNA, it is possible that ongoing surgical debris may overestimate the
4	relative decrease in tumor fraction based on the ratio of tumor-versus-non-tumor cfDNA.
5	This points to the importance of obtaining a sample immediately prior to
6	chemoradiation, when surgical debris has decreased. Moreover, while some post-
7	resection cfDNA may be attributable to debris, it remains to be established in gliomas
8	whether post-resection cfDNA levels correlate with patient prognosis, as has been
9	identified in other cancer types ^{43, 44} .
10	In patient 79, new variants were detected on POD2 after resection. Prior studies,
11	including in glioma, reported that numerous mutations were detected in CSF or plasma,
12	but not in the original tumor tissue ^{27, 45} . When CSF is obtained prior to surgical
13	resection, it may only contact one portion of the tumor, if at all, depending on the
14	anatomical location. However, resection can then increase CSF contact with new areas
15	of the infiltrative tumor margin as compared to CSF obtained prior to resection ^{28, 46} . As
16	such, it may be helpful to obtain both a pre-resection and post-resection/pre-
17	chemoradiation sample to determine the full spectrum of detectable tumor mutations for
18	longitudinal monitoring. The latter post-resection sample may then serve as the baseline
19	sample for monitoring disease burden and treatment response.
20	Prior studies have demonstrated that tumor contact with CSF, as well as tumor
21	size and grade, are key factors for detection of tumor cfDNA in CSF ^{28, 31, 32, 46} . One
22	study in 21 medulloblastomas, ependymomas, and high-grade gliomas demonstrated
23	that CSF cfDNA could be detected in tumors with CSF contact, whereas no cfDNA was

found in tumors that were distant from CSF²⁸. Multiple prior studies in other cancer types have noted the superiority of proximal fluids for cfDNA detection^{23, 25}. As such, use of CSF access devices in a resection cavity, as performed in our study, is a particularly attractive option for longitudinal CSF acquisition, allowing for close access to the source of the cfDNA. As most gliomas recur around the previous resection cavity^{47,} disease progression should be detectable. However, this needs to be demonstrated in a larger cohort of patients.

8 Our observational case series is intended for hypothesis generation and has 9 numerous limitations. Pre-chemoradiation CSF was not always obtained. CSF cfDNA 10 was also not analyzable in 5/35 samples and CSF cfDNA was not always abundant 11 enough to allow for NGS at each timepoint, hence only LP-WGS could be performed, 12 resulting in missing VAF data. To minimize false positives in CNB calls, intracranial non-13 tumor control CSF samples will need to be evaluated. Identification of thresholds of 14 change indicative of changes in disease burden will be needed to determine whether 15 changes in cfDNA-associated measures could adjudicate radiographic progression versus treatment effect or predict disease recurrence⁴⁹⁻⁵². When available, multiple 16 independent -omics in the same CSF sample, (e.g., D-2-HG) may increase confidence 17 18 in interpreting cfDNA changes.

19 CONCLUSION

Longitudinal acquisition of intracranial CSF cfDNA is feasible and can generate hypotheses regarding the impact of treatment and progression on cfDNA throughout a patient's disease course. Further studies are needed to determine the thresholds of change in cfDNA metrics that may correlate with changes in disease burden.

1	FUNDING: CRC was supported by the National Institute of Health T32GM145408. AMC
2	was supported by NIH T32GM00868. TCB, TJK, SHK, and JEP were supported by
3	NINDS R61 NS122096. TCB was supported by the Mayo Clinic Center for
4	Individualized Medicine and CCaTS award UL1TR002377, the American Brain Tumor
5	Association, Brains Together for the Cure, Humor to fight the Tumor, and Lucius &
6	Terrie McKelvey.
7	AUTHORSHIP:
8	- Study design and conception: TCB, CRC, LPC, AMC, SJ, PD
9	- Sample acquisition: CLN, KMA, NC, IJT, NM, TCB
10	- Sample processing and extraction: CRC, WM, SI, KG, ABZ, MDH, AEW
11	- Analyzed data: CRC, TCB, XD, CD, TJK, RBJ, PD, SJ
12	- Critically reviewed manuscript: all authors
13	DATA AVAILABILITY: All data are available as supplementary files.
14	ETHICS: This study was approved by the Mayo Clinic Institutional Review Board and all
15	participants provided their consent to participate in this study. This study was performed
16	in accordance with the Declaration of Helsinki.
17	CONSENT: All participants have provided consent for publication.
18	ACKNOWLEDGMENTS: We thank our patients and their families for their participation
19	in this study. We thank the Mayo Clinic Neurosurgery Clinical Research, neurosurgery
20	residents, and surgical team for their technical and research support.
21	CONFLICT OF INTEREST: Xiaoxi Dong, Chao Dai, Wei Mo, Pan Du, and Shidong Jia
22	report employment at Predicine, Inc. Wei Mo, Pan Du, and Shidong Jia also report stock
23	and other ownership interests in Predicine, Inc.

1 **FIGURE LEGENDS**:

2 Figure 1. Longitudinal cerebrospinal fluid cell-free DNA from patient 24 (recurrent

3 glioblastoma). (A) The timeline of the clinical course of patient 24 is depicted starting from post-operative (POD) 0, the day of resection for her recurrent GBM. Black X 4 5 indicates when CSF samples were obtained and sequenced: red X indicates when CSF 6 was sampled but had insufficient cfDNA for analysis. Correlative MRIs are shown for 7 each timepoint. (B) (i) Total cell-free (cfDNA) abundance, (ii) tumor fraction, and (iii) 8 copy number burden (CNB) were calculated from each CSF sample. CNB<7.5 (grey 9 box) is below the limit of quantification. (C)(i) Copy number plots were generated for 10 each CSF sample: POD118 is shown, and (ii) The variant allele frequencies (VAFs) 11 were calculated for the two samples where sufficient cfDNA was obtained for nextgeneration sequencing (NGS), at POD26 and 118. (D) Observations and guestions 12 13 were raised by patient 24's data. Red X = CSF obtained, insufficient cfDNA for testing. 14 Figure 2. Longitudinal cerebrospinal fluid cell-free DNA from patient 78 15 (glioblastoma). (A) The timeline of the clinical course of patient 78 is depicted starting 16 from post-operative (POD) 0, the day of resection for his primary GBM. On POD0, both 17 CSF (solid circle) and cyst fluid (hollow circle) were analyzed. The patient underwent 18 treatment with pembrolizumab in addition to standard chemoradiation. Black X indicates 19 when CSF samples were obtained and sequenced; red X indicates when CSF was 20 sampled but had insufficient cfDNA for analysis. Correlative MRIs are shown for each 21 timepoint. (B)(i) Total cell-free DNA (cfDNA) abundance, (ii) tumor fraction, and (iii) 22 copy number burden (CNB) were calculated from each CSF sample. (C)(i-ii) Copy 23 number plots were generated for each sample; POD0 from the cyst fluid and POD202

1 are shown. (iii) Fishplot depicting the variant allele frequency of five detected mutations 2 from POD0 to 471. (D) Observations and questions were raised by patient 78's data. 3 Red X = CSF obtained, insufficient cfDNA for testing. 4 Figure 3. Longitudinal cerebrospinal fluid cell-free DNA from patient 79 5 (glioblastoma, mismatch repair deficient). (A) The timeline of the clinical course of patient 79 is depicted starting from post-operative (POD) 0, the day of resection for her 6 7 glioblastoma that was mismatch repair deficient. She also underwent treatment with 8 pembrolizumab in addition to standard chemoradiation. Black X indicates when CSF 9 samples were obtained and sequenced; red X indicates when CSF was sampled but 10 had insufficient cfDNA for analysis. Correlative MRIs are shown for each timepoint. 11 Dashed lines = missing data between two points. (B)(i) Total cell-free DNA (cfDNA) 12 abundance, (ii) tumor fraction, and (iii) copy number burden (CNB) were calculated 13 from each CSF sample. (C)(i-iii) Copy number plots were generated for each CSF 14 sample; POD0, 36, and 310 are shown, and (iv) fishplot depicting the variant allele 15 frequency of numerous detected mutations from POD0 to 493. (D) Observations and 16 questions were raised by patient 79's data. Red X = CSF obtained, insufficient cfDNA 17 for testing.

18 Figure 4. Longitudinal cerebrospinal fluid cell-free DNA from patient 98

(astrocytoma, IDH mutant, CNS WHO grade 4). (A) The timeline of the clinical course
of patient 98 is depicted starting from post-operative (POD) 0, the day of resection for
his astrocytoma, IDH mutant, CNS WHO grade 4. Black X indicates when CSF samples
were obtained and sequenced; red X indicates when CSF was sampled but had
insufficient cfDNA for analysis. (B) (i) Total cell-free DNA (cfDNA) abundance, (ii) tumor

fraction, and (iii) copy number burden (CNB) were calculated from each CSF sample.
Additionally, (iv) volumetrics was performed to calculate the enhancing tumor volume
(cm ³) from each timepoint. The variant allele frequency (VAF) for the IDH1 mutation and
the levels of D-2-hydroxyglutarate (D-2-HG, in μM) were also quantified at each
timepoint. Hollow triangle: no IDH1 VAF detected. (C)(i-ii) Copy number plots were
generated for each CSF sample; POD0 and 305 are shown. (iii) Fishplot depicting the
VAFs of six detected mutations from POD0 to 361. (D) Observations and questions
were raised by patient 98's data.
Figure 5. Longitudinal cerebrospinal fluid cell-free DNA from patient 138
(astrocytoma, IDH mutant, grade 4). (A) The timeline of the clinical course of patient
138 is depicted starting from post-operative (POD) 0, the day of resection for his
astrocytoma, IDH mutant, grade 4. Black X indicates when CSF samples were obtained
and sequenced; red X indicates when CSF was sampled but had insufficient cfDNA for
analysis. (B)(i) Total cell-free DNA (cfDNA) abundance, (ii) tumor fraction, and (iii) copy
number burden (CNB) were calculated from each CSF sample. (iv) The variant allele
frequency (VAF) for the IDH1 mutation and the levels of D-2-hydroxyglutarate (D-2-HG,
in μ M) were quantified at each timepoint. (C)(i-ii) Copy number plots were generated for
each sample; POD0 and 214 shown, as well as (iii) a fishplot depicting the VAFs of
mutations from POD0 to 214. (D) Observations and questions were raised by patient
138's data.

1 REFERENCES

Johnson BE, Creason AL, Stommel JM, et al. An omic and multidimensional spatial atlas
 from serial biopsies of an evolving metastatic breast cancer. *Cell Rep Med*. Feb 15
 2022;3(2):100525. doi:10.1016/j.xcrm.2022.100525

5 2. Li A, Keck JM, Parmar S, et al. Characterizing advanced breast cancer heterogeneity 6 and treatment resistance through serial biopsies and comprehensive analytics. *npj Precision* 7 *Oncology*. 2021/03/26 2021;5(1):28. doi:10.1038/s41698-021-00165-4

8 3. Daud AI, Wolchok JD, Robert C, et al. Programmed Death-Ligand 1 Expression and 9 Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma. *Journal of* 10 *Clinical Oncology*. 2016;34(34):4102-4109. doi:10.1200/jco.2016.67.2477

Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat with or without
 rituximab in relapsed diffuse large B-cell lymphoma. *Blood*. 2016;128(2):185-194.
 doi:10.1182/blood-2016-02-699520

Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the
mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic
study in patients with advanced solid tumors. *J Clin Oncol.* Apr 1 2008;26(10):1603-10.

17 doi:10.1200/jco.2007.14.5482

18 6. McFaline-Figueroa JR, Wen PY. Negative trials over and over again: How can we do 19 better? *Neuro-Oncology*. 2022;25(1):1-3. doi:10.1093/neuonc/noac226

20 7. Singh K, Hotchkiss KM, Parney IF, et al. Correcting the drug development paradigm for
21 glioblastoma requires serial tissue sampling. *Nat Med.* Oct 2023;29(10):2402-2405.
22 doi:10.1038/s41591-023-02464-8

Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of
 radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. *Radiology*.
 Nov 2000;217(2):377-84. doi:10.1148/radiology.217.2.r00nv36377

van Dijken BRJ, van Laar PJ, Holtman GA, van der Hoorn A. Diagnostic accuracy of
 magnetic resonance imaging techniques for treatment response evaluation in patients with high grade glioma, a systematic review and meta-analysis. *Eur Radiol*. Oct 2017;27(10):4129-4144.
 doi:10.1007/s00330-017-4789-9

30 10. Wadden J, Ravi K, John V, Babila CM, Koschmann C. Cell-Free Tumor DNA (cf-tDNA)

Liquid Biopsy: Current Methods and Use in Brain Tumor Immunotherapy. *Front Immunol.* 2022;13:882452. doi:10.3389/fimmu.2022.882452

Bagley SJ, Nabavizadeh SA, Mays JJ, et al. Clinical utility of plasma cell-free DNA in
 adult patients with newly diagnosed glioblastoma: a pilot prospective study. *Clinical Cancer Research.* 2020;26(2):397-407.

Alix-Panabières C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application.
 Cancer Discovery. 2021;11(4):858-873. doi:10.1158/2159-8290.Cd-20-1311

38 13. Soffietti R, Bettegowda C, Mellinghoff IK, et al. Liquid biopsy in gliomas: A RANO review

and proposals for clinical applications. *Neuro Oncol.* Jun 1 2022;24(6):855-871.

40 doi:10.1093/neuonc/noac004

41 14. Bidard FC, Hardy-Bessard AC, Dalenc F, et al. Switch to fulvestrant and palbociclib

versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase
inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

44 Lancet Oncol. Nov 2022;23(11):1367-1377. doi:10.1016/s1470-2045(22)00555-1

Tie J, Cohen JD, Lahouel K, et al. Circulating Tumor DNA Analysis Guiding Adjuvant
Therapy in Stage II Colon Cancer. *New England Journal of Medicine*. 2022;386(24):2261-2272.
doi:10.1056/NEJMoa2200075

48 16. Taïeb J, Benhaim L, Laurent Puig P, et al. "Decision for adjuvant treatment in stage II

49 colon cancer based on circulating tumor DNA: The CIRCULATE-PRODIGE 70 trial". *Digestive*

50 and Liver Disease. 2020/07/01/ 2020;52(7):730-733. doi:10.1016/j.dld.2020.04.010

1 17. Nakamura Y, Okamoto W, Kato T, et al. Circulating tumor DNA-guided treatment with 2 pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. 3 Nature Medicine. 2021/11/01 2021;27(11):1899-1903. doi:10.1038/s41591-021-01553-w 4 Goodall J, Mateo J, Yuan W, et al. Circulating Cell-Free DNA to Guide Prostate Cancer 18. 5 Treatment with PARP Inhibition. Cancer Discov. Sep 2017;7(9):1006-1017. doi:10.1158/2159-6 8290.Cd-17-0261 7 Kim ST, Banks KC, Lee S-H, et al. Prospective Feasibility Study for Using Cell-Free 19. 8 Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim 9 Analysis. JCO Precision Oncology. 2017;(1):1-15. doi:10.1200/po.16.00059 10 20. Zill OA, Banks KC, Fairclough SR, et al. The landscape of actionable genomic 11 alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clinical 12 Cancer Research. 2018;24(15):3528-3538. 13 Bettegowda C, Sausen M, Leary RJ, et al. Detection of Circulating Tumor DNA in Early-21. 14 and Late-Stage Human Malignancies. Science Translational Medicine. 2014;6(224):224ra24-15 224ra24. doi:doi:10.1126/scitranslmed.3007094 16 McMahon JT, Studer M, Ulrich B, et al. Circulating Tumor DNA in Adults With Glioma: A 22. 17 Systematic Review and Meta-Analysis of Biomarker Performance. Neurosurgery. Aug 1 18 2022;91(2):231-238. doi:10.1227/neu.0000000000001982 19 Drabovich AP, Saraon P, Jarvi K, Diamandis EP. Seminal plasma as a diagnostic fluid 23. 20 for male reproductive system disorders. Nature Reviews Urology. 2014/05/01 2014;11(5):278-21 288. doi:10.1038/nrurol.2014.74 22 Kim Y, Jeon J, Mejia S, et al. Targeted proteomics identifies liquid-biopsy signatures for 24. 23 extracapsular prostate cancer. Nature communications. 2016;7(1):11906. 24 Teng P-n, Bateman NW, Hood BL, Conrads TP. Advances in proximal fluid proteomics 25. 25 for disease biomarker discovery. Journal of proteome research. 2010;9(12):6091-6100. 26 26. Mair R, Mouliere F. Cell-free DNA technologies for the analysis of brain cancer. British 27 Journal of Cancer. 2022/02/01 2022;126(3):371-378. doi:10.1038/s41416-021-01594-5 28 De Mattos-Arruda L, Mayor R, Ng CK, et al. Cerebrospinal fluid-derived circulating 27. 29 tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature 30 communications. 2015;6(1):8839. 31 28. Wang Y, Springer S, Zhang M, et al. Detection of tumor-derived DNA in cerebrospinal 32 fluid of patients with primary tumors of the brain and spinal cord. Proceedings of the National 33 Academy of Sciences. 2015;112(31):9704-9709. doi:doi:10.1073/pnas.1511694112 34 Pan W, Gu W, Nagpal S, Gephart MH, Quake SR. Brain tumor mutations detected in 29. 35 cerebral spinal fluid. Clin Chem. Mar 2015;61(3):514-22. doi:10.1373/clinchem.2014.235457 36 30. Pan C, Diplas BH, Chen X, et al. Molecular profiling of tumors of the brainstem by 37 sequencing of CSF-derived circulating tumor DNA. Acta neuropathologica. 2019;137:297-306. 38 Martínez-Ricarte F, Mayor R, Martínez-Sáez E, et al. Molecular Diagnosis of Diffuse 31. 39 Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. 40 Clinical Cancer Research. 2018;24(12):2812-2819. doi:10.1158/1078-0432.Ccr-17-3800 41 32. Mouliere F, Mair R, Chandrananda D, et al. Detection of cell-free DNA fragmentation 42 and copy number alterations in cerebrospinal fluid from glioma patients. EMBO Molecular 43 *Medicine*. 2018;10(12):e9323. doi:10.15252/emmm.201809323 44 33. Pagès M, Rotem D, Gydush G, et al. Liquid biopsy detection of genomic alterations in 45 pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. Neuro-Oncology. 46 2022;24(8):1352-1363. doi:10.1093/neuonc/noab299 47 Dong X, Zheng T, Zhang M, et al. Circulating Cell-Free DNA-Based Detection of Tumor 34. 48 Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer. 49 Front Oncol. 2021;11:720727. doi:10.3389/fonc.2021.720727

1 35. Huelster HL, Gould B, Schiftan EA, et al. Novel Use of Circulating Tumor DNA to Identify 2 Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. European Urology. 3 2023/10/04/ 2023;doi:10.1016/j.eururo.2023.09.017 4 36. Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in 5 symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038-6 2050. doi:10.1182/blood.2020006844 7 Wang J, Liu Y, Liang Y, et al. Clinicopathologic features, genomic profiles and outcomes 37. 8 of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) 9 metastatic breast cancer patients. Front Oncol. 2023;13:1152575. 10 doi:10.3389/fonc.2023.1152575 11 38. Nebot-Bral L, Brandao D, Verlingue L, et al. Hypermutated tumours in the era of 12 immunotherapy: The paradigm of personalised medicine. Eur J Cancer. Oct 2017;84:290-303. 13 doi:10.1016/j.ejca.2017.07.026 14 Han S, Liu Y, Cai SJ, et al. IDH mutation in glioma: molecular mechanisms and potential 39. 15 therapeutic targets. British Journal of Cancer. 2020/05/01 2020;122(11):1580-1589. 16 doi:10.1038/s41416-020-0814-x 17 Henriksen TV, Reinert T, Christensen E, et al. The effect of surgical trauma on 40. 18 circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA. 19 Mol Oncol. Aug 2020;14(8):1670-1679. doi:10.1002/1878-0261.12729 20 41. Rosen AW, Gögenur M, Paulsen IW, et al. Perioperative changes in cell-free DNA for 21 patients undergoing surgery for colon cancer. BMC Gastroenterology. 2022/04/06 22 2022;22(1):168. doi:10.1186/s12876-022-02217-w 23 Konishi S, Narita T, Hatakeyama S, et al. Utility of total cell-free DNA levels for surgical 42. 24 damage evaluation in patients with urological surgeries. Scientific Reports. 2021/11/11 25 2021;11(1):22103. doi:10.1038/s41598-021-01430-z 26 43. Fernandez-Garcia D, Hills A, Page K, et al. Plasma cell-free DNA (cfDNA) as a 27 predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Res. 28 Dec 19 2019;21(1):149. doi:10.1186/s13058-019-1235-8 29 Koukourakis MI, Xanthopoulou E, Koukourakis IM, et al. Circulating Plasma Cell-free 44. 30 DNA (cfDNA) as a Predictive Biomarker for Radiotherapy: Results from a Prospective Trial in 31 Head and Neck Cancer. Cancer Diagn Progn. Sep-Oct 2023;3(5):551-557. 32 doi:10.21873/cdp.10254 33 45. Razavi P, Li BT, Brown DN, et al. High-intensity sequencing reveals the sources of 34 plasma circulating cell-free DNA variants. Nature Medicine. 2019/12/01 2019;25(12):1928-1937. 35 doi:10.1038/s41591-019-0652-7 36 46. Miller AM, Shah RH, Pentsova EI, et al. Tracking tumour evolution in glioma through 37 liquid biopsies of cerebrospinal fluid. Nature. 2019/01/01 2019;565(7741):654-658. 38 doi:10.1038/s41586-019-0882-3 39 Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of 47. 40 recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys. 1992;24(1):55-7. doi:10.1016/0360-3016(92)91021-e 41 42 48. Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide 43 concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: 44 correlation with MGMT promoter methylation status. J Clin Oncol. 2009;27(8):1275-1279. 45 Chen X, Chang C-W, Spoerke JM, et al. Low-pass Whole-genome Sequencing of 49. 46 Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a 47 Squamous Lung Cancer Clinical Cohort. Clinical Cancer Research. 2019;25(7):2254-2263. 48 doi:10.1158/1078-0432.Ccr-18-1593 49 Huffman BM, Aushev VN, Budde GL, et al. Analysis of Circulating Tumor DNA to Predict 50. 50 Risk of Recurrence in Patients With Esophageal and Gastric Cancers. JCO Precision Oncology.

51 2022;(6):e2200420. doi:10.1200/po.22.00420

- Tie J, Cohen JD, Wang Y, et al. Circulating Tumor DNA Analyses as Markers of 1 51.
- 2 Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncol. Dec 3 1 2019;5(12):1710-1717. doi:10.1001/jamaoncol.2019.3616
- 4 5 Liu APY, Smith KS, Kumar R, et al. Serial assessment of measurable residual disease in 52.
- medulloblastoma liquid biopsies. Cancer Cell. Nov 8 2021;39(11):1519-1530.e4.
- 6 doi:10.1016/j.ccell.2021.09.012



Patient 78 - GBM









